ClinicalTrials.gg
CompletedNCT00875420Updated Sep 26, 2018Results posted

A Study to Evaluate the Effects of RAD1901 in the Treatment of Vasomotor Symptoms in Postmenopausal Women

A Phase 2 interventional study of RAD1901 and RAD1901 in Hot Flashes, sponsored by Radius Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to female participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-09-26.

Sponsored by Radius Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 193 studies in Hot Flashes with a site in United States — 26 open to participants now, 27 under way, 2 of them phase 3. Hot Flashes · United States.

Enrollment
81st of 180
100 · median 84
Started
2009
with 7 others
Phase 2
41 of 193
6 open now
Registered
75th of 193
by date

Among the 193 studies in Hot Flashes with a site in United States, this one is the 81st largest by enrollment of the 180 interventional ones that give a count, is one of 8 that started in 2009, is one of 41 in phase 2, and was the 75th registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

26 of the 193 studies in Hot Flashes with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 40 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 193 studies in Hot Flashes with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether RAD1901 is effective in decreasing hot flashes in postmenopausal women.

03

Conditions studied

  • Hot Flashes

Browse trials for

Keywords

  • hot flashes
  • hot flushes
  • vasomotor symptoms
  • postmenopausal
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have documented evidence of a minimum of 7 moderate to severe hot flashes per day, or 50 per week.
  2. Be in good general health as determined by medical history, physical examination, and inclusion procedures and is without evidence of any abnormalities.
  3. Have a normal pelvic assessment with no clinically significant signs on examination and pelvic ultrasound.
  4. Have a normal mammogram at the time of study screening.

Exclusion criteria

Exclusion Criteria:

  1. A history of chronic or recurrent renal, hepatic, pulmonary, allergic, cardiovascular, gastrointestinal, endocrine, central nervous system, hematologic, immunologic or metabolic diseases to a degree that would compromise patient safety or interfere with the interpretation of study data. A history of active presence of thrombophlebitis, thrombosis, thromboembolic disorders.
  2. A history of active presence of stroke, (TIA), heart attack or ischemic heart disease.
  3. Unexplained vaginal bleeding within the 3 months prior to study entry.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    RAD1901 10 mg

    Oral once a day for 28 days

    Drug: RAD1901

  • Experimental
    RAD1901 25 mg

    Oral once a day for 28 days

    Drug: RAD1901

  • Experimental
    RAD1901 50 mg

    Oral once a day for 28 days

    Drug: RAD1901

  • Experimental
    RAD1901 100 mg

    Oral once a day for 28 days

    Drug: RAD1901

  • Placebo comparator
    Placebo

    Oral once a day for 28 days

    Drug: Placebo

Interventions

  • 10 mg Oral once a day for 28 days.

  • 25 mg Oral once a day for 28 days

  • 50 mg Oral once a day for 28 days.

  • 100 mg Oral once a day for 28 days

  • DrugPlacebo

    Placebo Oral once a day for 28 days

06

What researchers measure

Primary outcomes

  1. Percent Change in Frequency of Hot Flashes Over Time

    Percent change of moderate and severe hot flash frequency at 4 weeks compared to baseline using weekly Subject diary data, in the intent-to-treat population.

    Time frame: Week 4 minus baseline week

  2. Percent Change in Composite Score Over Time

    Percent change in composite score (frequency x severity) of hot flashes (Mild=1, Moderate=2, Severe=3) at 4 weeks compared to baseline, in the intent-to-treat population.

    Time frame: Week 4 minus baseline week

Secondary outcomes

  1. Determine the Effects of RAD1901 on Follicular Stimulating Hormone (FSH) Over Time.

    Percent change in FSH at Day 29 compared to baseline, in the intent-to-treat population.

    Time frame: Day 29 minus baseline

  2. Determine the Effects of RAD1901 on Luteinizing Hormone (LH) Over Time.

    Percent change in LH levels at Day 29 compared to baseline, in the intent-to-treat population.

    Time frame: Day 29 minus baseline

07

Results

Posted Mar 26, 2012

Participant flow

Participant flow — Overall Study
MilestoneRAD1901 10 mgRAD1901 25 mgRAD1901 50 mgRAD1901 100 mgPlacebo
Started2220211819
Completed2018181617
Not completed22322
Withdrew: Adverse event01100
Withdrew: Inability to complete study procedures10111
Withdrew: Lost to follow-up10000
Withdrew: Personal reason00001
Withdrew: Prohibited medication00010
Withdrew: Sponsor decision01000
Withdrew: Withdrawal by subject00100

Outcome measures

PrimaryPercent Change in Frequency of Hot Flashes Over Time

Percent change of moderate and severe hot flash frequency at 4 weeks compared to baseline using weekly Subject diary data, in the intent-to-treat population.

Time frame:
Week 4 minus baseline week
Reported as:
Mean · Percent change from baseline
Percent Change in Frequency of Hot Flashes Over Time
Percent change from baselineRAD1901 10 mgRAD1901 25 mgRAD1901 50 mgRAD1901 100 mgPlacebo
Percent Change in Frequency of Hot Flashes Over Time-77.2 ± 20.43-51.8 ± 45.02-53.8 ± 39.16-67.0 ± 33.85-54.1 ± 37.72
SecondaryDetermine the Effects of RAD1901 on Follicular Stimulating Hormone (FSH) Over Time.

Percent change in FSH at Day 29 compared to baseline, in the intent-to-treat population.

Time frame:
Day 29 minus baseline
Reported as:
Mean · Percent change from baseline
Determine the Effects of RAD1901 on Follicular Stimulating Hormone (FSH) Over Time.
Percent change from baselineRAD1901 10 mgRAD1901 25 mgRAD1901 50 mgRAD1901 100 mgPlacebo
Determine the Effects of RAD1901 on Follicular Stimulating Hormone (FSH) Over Time.4.24 ± 34.077-6.56 ± 13.933-4.42 ± 24.381-3.26 ± 11.3738.67 ± 62.175
SecondaryDetermine the Effects of RAD1901 on Luteinizing Hormone (LH) Over Time.

Percent change in LH levels at Day 29 compared to baseline, in the intent-to-treat population.

Time frame:
Day 29 minus baseline
Reported as:
Mean · Percent change from baseline
Determine the Effects of RAD1901 on Luteinizing Hormone (LH) Over Time.
Percent change from baselineRAD1901 10 mgRAD1901 25 mgRAD1901 50 mgRAD1901 100 mgPlacebo
Determine the Effects of RAD1901 on Luteinizing Hormone (LH) Over Time.-12.81 ± 27.551-0.19 ± 19.573-10.94 ± 22.6093.57 ± 22.3926.70 ± 36.270
PrimaryPercent Change in Composite Score Over Time

Percent change in composite score (frequency x severity) of hot flashes (Mild=1, Moderate=2, Severe=3) at 4 weeks compared to baseline, in the intent-to-treat population.

Time frame:
Week 4 minus baseline week
Reported as:
Mean · Percent change from baseline
Percent Change in Composite Score Over Time
Percent change from baselineRAD1901 10 mgRAD1901 25 mgRAD1901 50 mgRAD1901 100 mgPlacebo
Percent Change in Composite Score Over Time-75.65 ± 18.655-55.48 ± 39.442-48.78 ± 39.806-66.21 ± 33.226-55.80 ± 35.523

Adverse events

Collected over Adverse events were collected for 2 months during this study; from start of treatment to the end-of-treatment visit (Day 29) and 30 days after end-of-treatment visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RAD1901 10 mg—0/22 (0%)16/22 (72.7%)
RAD1901 25 mg—0/20 (0%)14/20 (70%)
RAD1901 50 mg—0/21 (0%)14/21 (66.7%)
RAD1901 100 mg—0/18 (0%)14/18 (77.8%)
Placebo—0/19 (0%)11/19 (57.9%)
Most frequent other events
Showing 10 of 52
Most frequent other events
EventRAD1901 10 mgRAD1901 25 mgRAD1901 50 mgRAD1901 100 mgPlacebo
InfluenzaInfections and infestations2/224/202/211/180/19
HeadacheNervous system disorders4/222/202/212/182/19
GastritisGastrointestinal disorders3/221/201/212/180/19
HypocholesterolaemiaMetabolism and nutrition disorders3/221/200/210/180/19
DyspepsiaGastrointestinal disorders0/220/201/212/180/19
SomnolenceNervous system disorders0/220/200/210/182/19
HypertensionVascular disorders0/220/201/211/182/19
HyperchlorhydriaGastrointestinal disorders0/222/200/210/181/19
Urinary Tract InfectionInfections and infestations1/222/201/210/180/19
AnxietyPsychiatric disorders0/222/200/210/180/19

Baseline characteristics

Age, Continuous
Age, Continuous(years)RAD1901 10 mgRAD1901 25 mgRAD1901 50 mgRAD1901 100 mgPlaceboTotal
Mean53.5 ± 5.7455.2 ± 7.7453.7 ± 5.6855.7 ± 6.4553.8 ± 5.7454.3 ± 6.24
Sex: Female, Male
Sex: Female, Male(Participants)RAD1901 10 mgRAD1901 25 mgRAD1901 50 mgRAD1901 100 mgPlaceboTotal
Female2220211819100
Male000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RAD1901 10 mgRAD1901 25 mgRAD1901 50 mgRAD1901 100 mgPlaceboTotal
American Indian or Alaska Native000000
Asian000000
Native Hawaiian or Other Pacific Islander000000
Black or African American000000
White2220211819100
More than one race000000
Unknown or Not Reported000000
08

Study locations

1 site
  • Radius Health, Inc.
    Cambridge, Massachusetts 02139, United States
09

References and documents

Publications

  • Hattersley G, Harris AG, Simon JA, Constantine GD. Clinical investigation of RAD1901, a novel estrogen receptor ligand, for the treatment of postmenopausal vasomotor symptoms: a phase 2 randomized, placebo-controlled, double-blind, dose-ranging, proof-of-concept trial. Menopause. 2017 Jan;24(1):92-99. doi: 10.1097/GME.0000000000000726. PubMed 27575546 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Jan 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2012, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2009
First posted
Apr 3, 2009
Start
Mar 2009
Primary completionActual
Jan 2010
CompletionActual
Apr 2010
Results first posted
Mar 26, 2012
Last update
Sep 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00875420
Lead sponsor
Radius Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Apr 3, 2009
Start date
Mar 2009
Primary completion
Jan 2010
Completion
Apr 2010
Results posted
Mar 26, 2012
Last update
Sep 26, 2018

Study contacts

Medical Director
study director · Radius Health, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elacestrant

Start the discussion